{"id":3109,"date":"2022-04-29T15:32:20","date_gmt":"2022-04-29T05:32:20","guid":{"rendered":"https:\/\/orthocell.com\/us\/?p=3109"},"modified":"2022-04-29T15:32:20","modified_gmt":"2022-04-29T05:32:20","slug":"quarterly-report-period-to-31-march-2022","status":"publish","type":"post","link":"\/americas\/quarterly-report-period-to-31-march-2022\/","title":{"rendered":"Quarterly Report | Period To 31 March 2022"},"content":{"rendered":"<p>Orthocell has today published its Quarterly Report for the period ended 31 March 2022.<\/p>\n<p><strong>Standout achievements for this Quarter include:<\/strong><\/p>\n<ul>\n<li><strong>Remplir\u2122 nerve repair device receives Australian regulatory approval <\/strong>for introduction into the Australian nerve repair and regeneration market<\/li>\n<li><strong>Application for inclusion of Remplir\u2122 on the Prostheses List on track<\/strong> for submission in Q2 CY2022<\/li>\n<li><strong>Final Remplir\u2122 24 month results of all patients in the nerve regeneration study on track<\/strong> for Q2 CY2022<\/li>\n<li><strong>SignificantStriate+\u2122 US market entry progress <\/strong>with sale of over 1,500 Striate+\u2122 units achieved, and commencement of facility upgrade to enable scale up Striate+\u2122 manufacturing capacity to &gt;100,000 units per year<\/li>\n<li><strong>Striate+\u2122 distributor discussions progressed <\/strong>and the Company is in advanced discussions to engage its first US distributor and establish Striate+\u2122 as the premium dental membrane<\/li>\n<li><strong>The final data from the OrthoATI\u2122 Phase 2a study on track for Q2 CY2022<\/strong><\/li>\n<\/ul>\n<p><strong>\u00a0<\/strong><a href=\"https:\/\/bit.ly\/OCC_Quarterly_Mar\"><strong>Click here to read today\u2019s ASX release. <\/strong><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Orthocell has today published its Quarterly Report for the period ended 31 March 2022. Standout achievements for this Quarter include: Remplir\u2122 nerve repair device receives Australian regulatory approval for introduction into the Australian nerve repair and regeneration market Application for inclusion of Remplir\u2122 on the Prostheses List on track for submission in Q2 CY2022 Final [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":2509,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"footnotes":""},"categories":[2],"tags":[],"class_list":["post-3109","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company-news"],"aioseo_notices":[],"_links":{"self":[{"href":"\/americas\/wp-json\/wp\/v2\/posts\/3109","targetHints":{"allow":["GET"]}}],"collection":[{"href":"\/americas\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"\/americas\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"\/americas\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"\/americas\/wp-json\/wp\/v2\/comments?post=3109"}],"version-history":[{"count":1,"href":"\/americas\/wp-json\/wp\/v2\/posts\/3109\/revisions"}],"predecessor-version":[{"id":3110,"href":"\/americas\/wp-json\/wp\/v2\/posts\/3109\/revisions\/3110"}],"wp:featuredmedia":[{"embeddable":true,"href":"\/americas\/wp-json\/wp\/v2\/media\/2509"}],"wp:attachment":[{"href":"\/americas\/wp-json\/wp\/v2\/media?parent=3109"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"\/americas\/wp-json\/wp\/v2\/categories?post=3109"},{"taxonomy":"post_tag","embeddable":true,"href":"\/americas\/wp-json\/wp\/v2\/tags?post=3109"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}